glp-1 parkinson's disease Repurposing Receptor Agonists for Disease: Current Evidence and Future Opportunities | Pharmaceutical Medicine Neuroprotective Actions of Glucagon-Like Peptide-1

Prevention or delay of type 2 diabetes and associated comorbidities: Standards of medical care in diabetes-2022

477 SGLT2 inhibitors include canagliflozin, dapagliflozin, and empagliflozin that have been approved by the FDA for combined use with diet and exercise to lower blood sugar and excessive insulin secretion in adults with type 2 diabetes

BPC-157 has been shown to: Increase fibroblast recruitment Speed up collagen deposition Improve tendon-to-bone interface healing Reinforce ligament remodeling after trauma This makes it highly effective for: Partial tendon tears Post-surgical repair Muscle strains and chronic tendonitis Application of BPC-157 significantly improved fibroblast activity and collagen fiber orientation in Achilles tendon repair models. Chang et al., American Journal of Sports Medicine 3

1 Clinical data demonstrating long-term advantage of GLP-1R medicines Recent data shared about tirzepatide (Zepbound and Mounjaro) by Eli Lilly and Company revealed the promise of these drugs as long-term treatments for obesity and pre-diabetes